CLINICAL_TRIALS
trial_result
· 2015-03-13
Clinical Trial Update: Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) [Phase 2]
Summary
Phase 2 clinical trial results showing safety and efficacy of PCI-32765 (ibrutinib) in relapsed/refractory mantle cell lymphoma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pharmacyclics LLC. | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2015-03-13